Onvansertib

CAS No.

1034616-18-6

MDL No.

MFCD26793840

C₂₄H₂₇F₃N₈O₃

532.50

InChI Key

QHLVBNKYJGBCQJ-UHFFFAOYSA-N

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

On Request

Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1034616-18-6
Product Name	Onvansertib

Biological Targets

PLK1

Associated Conditions

neoplasm·inflammatory breast carcinoma·pancreatic carcinoma·acute myeloid leukemia·prostate cancer·

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Onvansertib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.

[Plastein synthesis as a possibility of modifying functional properties of proteins].

Documentation

Similar Products

N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide

NMS-P715

Atorvastatin Cyclic Sodium Salt (Isopropyl) Impurity

Cefilavancin

DBCO-|A-Glu-PEG12-Exatecan

Navelbine ditartrate (TN)